Related Experiment Video
Updated: Mar 24, 2026
10:37
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
8.7K
The Mexican consensus on irritable bowel syndrome.
R Carmona-Sánchez1, M E Icaza-Chávez2, M V Bielsa-Fernández3
1Práctica privada, San Luis Potosí, S.L.P., México.
Revista De Gastroenterologia De Mexico
|March 16, 2016
Summary
This review updates Irritable Bowel Syndrome (IBS) guidelines with new evidence since 2009. It incorporates international research and Mexican studies on IBS epidemiology, diagnosis, and treatment.
Area of Science:
- Gastroenterology
- Clinical Practice Guidelines
Background:
- Significant advancements in understanding Irritable Bowel Syndrome (IBS) have occurred since the 2009 Mexican Association of Gastroenterology guidelines.
- New insights into IBS epidemiology, pathophysiology, diagnosis, and treatment necessitate an update.
Purpose of the Study:
- To provide a consensus review of current Irritable Bowel Syndrome (IBS) knowledge.
- To update the 2009 guidelines by integrating recent international scientific evidence, with a focus on Mexican research.
Main Methods:
- A comprehensive literature search of PubMed (2009-2015) and manual searches.
- Inclusion of English and Spanish articles, prioritizing high-level evidence like consensuses, guidelines, systematic reviews, and meta-analyses.
- Utilized the Delphi method for statement formulation and voting by 24 gastroenterologists, with evidence and recommendations graded using the GRADE system.
Main Results:
- Developed 48 statements updating information on Irritable Bowel Syndrome (IBS).
- Incorporated new data on the significance of exercise and diet, diagnostic approaches, and contemporary therapeutic options.
- Analyzed recent findings with rigorous scientific evaluation, reflecting advancements in the last five years.
Conclusions:
- Presents a consensus review of key Irritable Bowel Syndrome (IBS) research advancements.
- Updates and complements the 2009 guidelines based on current scientific evidence.
- Highlights the inclusion of multiple studies conducted within Mexico.
Related Concept Videos
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
1.0K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.0K
01:17Irritable Bowel Syndrome I: Introduction
1.4K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.4K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
855
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
855
01:21Drugs for Treatment of Constipation-Predominant IBS
1.2K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.2K
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
963
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
963
01:17Chronic Bowel Disorders: Introduction
896
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
896